Compare BIP & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIP | VTRS |
|---|---|---|
| Founded | 2007 | 1961 |
| Country | Bermuda | United States |
| Employees | N/A | 30000 |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 17.5B |
| IPO Year | N/A | 2019 |
| Metric | BIP | VTRS |
|---|---|---|
| Price | $36.23 | $14.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $39.50 | $13.50 |
| AVG Volume (30 Days) | 933.7K | ★ 8.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.23% | 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | N/A | $4.41 |
| Revenue Next Year | $7.61 | $1.96 |
| P/E Ratio | $39.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.63 | $8.19 |
| 52 Week High | $40.32 | $16.47 |
| Indicator | BIP | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 64.68 |
| Support Level | $34.69 | $12.90 |
| Resistance Level | $36.94 | $15.22 |
| Average True Range (ATR) | 0.92 | 0.39 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 74.28 | 88.03 |
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.